We are thrilled to support the work of Mesentech, Inc. in a new funding collaborative with CureDuchenne Ventures. Together, our PRI funding will support Mesentech’s pediatric-first approach to developing its bone-targeting therapeutic, which can increase bone mass to strengthen the skeleton and holds promise for a variety of child health conditions.
Access the funding collaborative announcement from CureDuchenne Ventures here and learn more about Mesentech here.
The Charles H. Hood Foundation is pleased to announce that applications are now open for the September 2026 funding cycle of the Child Health Research Awards Program, which supports early-career investigators pursuing innovative research to improve child health.
The Charles H. Hood Foundation is pleased to announce that applications are now open for the September 2026 funding cycle of the Child Health Research Awards Program, which supports early-career investigators pursuing innovative research to improve child health.
The Charles H. Hood Foundation is delighted to announce that Camilia (“Cami”) R. Martin, MD, MS, has joined the Foundation as Chief Scientific Officer. In this leadership role, Dr. Martin will steward and advance the Hood Foundation’s child health research portfolio, overseeing pediatric research awards and serving as a strategic scientific partner across initiatives, including the Hood Pediatric Innovation Hub.
